Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 30, 2021 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate if combined CD19 and CD22 chimeric antigen receptor (CAR) T-cell therapies could be used to treat patients with relapsed acute lymphoblastic leukemia (ALL) after transplant.  

This study concluded that this combination improved long-term survival for these patients. 

Some background

The prognosis of relapsed ALL after allogeneic (donor) transplantation is poor when treated with standard approaches. CAR-T cell therapies involve taking immune cells called T-cells from the patient and modifying them in the lab to detect and kill cancer cells. They can be engineered to attach to certain proteins on ALL cells such as CD19 or CD22. 

CD19 or CD22 targeted CAR T-cells have shown high complete remission (CR) rates in relapsed/refractory (R/R) ALL. However but it cannot maintain a durable remission in most patients. It was unknown if a combination of CD19 and CD22 CAR-T cells could improve the outcomes for patients with R/R ALL.  

Methods & findings

This study involved 21 patients with ALL who had both CD19 and CD22 proteins on leukemia cells. All patients had relapsed after stem cell transplant. Patients were treated with both CD19 and CD22 CAR-T cells within 3 months. Patients were followed up for an average of 19.7 months. 

88.5% of patients were alive after 18 months. 67.5% were alive without complications from ALL after 18 months. 

CAR-T associated graft-versus-host-disease (GVHD) occurred in 23% of patients. GVHD is where the transplanted cells attack the patient.  

The bottom line

This study concluded that combined CD19 and CD22 CAR-T cell therapy can improve long-term survival for patients with post-transplant relapsed ALL. 

The fine print

This study included a very small number of participants. Most patients were very young, with an average age of 21. The effects of this combination in older patients are not known. Further studies are needed.

Published By :

American Journal of Hematology

Date :

Mar 16, 2021

Original Title :

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

click here to get personalized updates